Synthesis of a Novel Thiazolidinedione and Evaluation of Its Modulatory Effect on IFN-γ, IL-6, IL-17A, and IL-22 Production in PBMCs from Rheumatoid Arthritis Patients

Table 1

Demographic, clinical, and laboratory presentation of the patients with RA.

Number of patients	9
Age (years)
Mean (range)	52.6 (30–69)
Sex
Female/male	9/0
Disease duration (years)
Mean (range)	6 years (0.1–16.2)
Rheumatoid factor
Positive/negative	8/1
Treatment
Nonsteroidal anti-inflammatory drugs	1
Steroids	8
Methotrexate	4
Leflunomide	2
Antimalarial agents	1
Biologic therapy	—
Disease activity
DAS28
Clinical remission	—
Mild disease	4
Moderate disease	2
Severe disease	3
CDAI
Clinical remission	—
Mild disease	—
Moderate disease	5
Severe disease	4